Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Xemilofiban/orbofiban: insight into drug development.

R Anders1, J Kleiman, N Nicholson

  • 1Searle/Pharmacia Pharmaceuticals, 5200 Old Orchard Road, OO-II-3102, Skokie, IL 60077, USA. robert.j.anders@monsanto.com

Cardiovascular Drug Reviews
|August 3, 2001
PubMed
Summary

Oral glycoprotein IIb/IIIa receptor antagonists like xemilofiban and orbofiban were evaluated for chronic use in unstable angina. Despite promising mechanisms, pivotal trials did not demonstrate significant clinical benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.

British journal of haematology·2024
Same author

Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.

British journal of haematology·2023
Same author

Evidence for X(3872) in Pb-Pb Collisions and Studies of its Prompt Production at sqrt[s_{NN}]=5.02  TeV.

Physical review letters·2022
Same author

Measurement of single-diffractive dijet production in proton-proton collisions at <math> </math> with the CMS and TOTEM experiments.

The European physical journal. C, Particles and fields·2020
Same author

Evidence for Top Quark Production in Nucleus-Nucleus Collisions.

Physical review letters·2020
Same author

A Deep Neural Network for Simultaneous Estimation of b Jet Energy and Resolution.

Computing and software for big science·2020

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Intravenous glycoprotein IIb/IIIa receptor antagonists show success in acute settings like unstable angina and percutaneous interventions.
  • The potential for chronic platelet aggregation inhibition led to the development of oral agents for longer-term use.

Purpose of the Study:

  • To review and evaluate the development programs of oral glycoprotein IIb/IIIa receptor antagonists, specifically xemilofiban and orbofiban.
  • To understand the selection process for therapeutic targets based on pharmacokinetic and pharmacodynamic profiles.
  • To analyze pivotal Phase III trial results and identify reasons for the lack of demonstrated benefit.

Main Methods:

  • Review of development programs for xemilofiban and orbofiban.
  • Analysis of pharmacokinetic and pharmacodynamic data.

Related Experiment Videos

  • Evaluation of pivotal Phase III clinical trial outcomes.

    • Main Results:

    • The development of oral glycoprotein IIb/IIIa antagonists was explored for chronic administration in cardiovascular conditions.
    • Pivotal Phase III trials for xemilofiban and orbofiban were conducted to assess efficacy and safety.
    • These agents did not show significant clinical benefit in the trials reviewed.

    Conclusions:

    • Despite a strong theoretical basis and promising initial research, oral glycoprotein IIb/IIIa receptor antagonists did not translate into significant clinical benefits in Phase III trials.
    • Further investigation into the complex pharmacokinetic and pharmacodynamic responses was insufficient to overcome the lack of efficacy.
    • The development of these specific agents for chronic use in unstable angina was ultimately unsuccessful.